Sridama V, Hara Y, Fauchet R, DeGroot L J
Cancer. 1985 Sep 1;56(5):1086-8. doi: 10.1002/1097-0142(19850901)56:5<1086::aid-cncr2820560521>3.0.co;2-9.
Seventy-four American white thyroid cancer patients were typed for HLA-A, B, and DR antigens. A significant increase in HLA-DR7 was found in the nonradiation-associated thyroid cancer patients (42.5%, 20/47 cases), compared to 22.8% of 979 normal controls. The association is stronger in the follicular and mixed papillary-follicular subgroup (52.0%, 13/25 cases, P corrected less than 0.01). The occurrence of various malignancies in family members was found in 57.9% of HLA-DR7 positive patients, versus 20% of HLA-DR7 negative patients, in a retrospective record review. Although the frequency of HLA-DR7 was not increased in the radiation-associated thyroid cancer patients (22.2%, 6/27 cases), the interval from the irradiation date to the onset date of thyroid cancer was shorter in HLA-DR7 positive cases (17.3 +/- 6.2 years) than in HLA-DR7 negative patients (29.4 +/- 11.5 years). This data suggest that HLA-DR7 is associated with and may influence development of thyroid cancer.
对74名美国白人甲状腺癌患者进行了HLA - A、B和DR抗原分型。与979名正常对照者中的22.8%相比，在非辐射相关甲状腺癌患者中发现HLA - DR7显著增加（42.5%，20/47例）。在滤泡性和乳头状 - 滤泡性混合亚组中这种关联更强（52.0%，13/25例，校正P值小于0.01）。通过回顾性记录审查发现，HLA - DR7阳性患者中有57.9%的家庭成员发生了各种恶性肿瘤，而HLA - DR7阴性患者中这一比例为20%。虽然在辐射相关甲状腺癌患者中HLA - DR7的频率没有增加（22.2%，6/27例），但HLA - DR7阳性病例从照射日期到甲状腺癌发病日期的间隔（17.3±6.2年）比HLA - DR7阴性患者（29.4±11.5年）短。这些数据表明HLA - DR7与甲状腺癌的发生有关并可能影响其发展。
